SEPN

Septerna, Inc. (SEPN) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Septerna, Inc. is a biotechnology company focused on G protein-coupled receptor (GPCR) oral small molecule drug discovery using its proprietary Native Complex Platform. The company operates in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. As of June 30, 2025, the company had no approved products and generated revenue solely from research services.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Expenses: Total operating expenses rose by $21.0 million (61%) for the six months ended June 30, 2025, compared to the same period in 2024. This was driven by a $13.3 million increase in R&D and a $7.7 million increase in G&A.
• R&D Drivers: Higher R&D costs were primarily due to increased direct costs for clinical and preclinical programs (including SEP-631 and PTH1R), higher employee-related costs due to headcount growth, and expanded facility costs. The company discontinued the SEP-786 clinical study in February 2025.
• G&A Drivers: Increased G&A expenses were attributed to higher legal and consulting fees associated with operating as a public company post-IPO (October 2024), increased headcount, and higher IT expenses.
• Interest Income: Interest income increased significantly to $8.6 million for the six months ended June 30, 2025, compared to $2.8 million in the prior year, due to higher interest rates and larger cash balances.
• Revenue Decline: Service revenue decreased to $0.3 million for the six months ended June 30, 2025, from $0.7 million in the prior year, reflecting the completion of certain research service milestones.

Guidance, Outlook, and Material Events

• Novo Nordisk Collaboration: In May 2025, Septerna entered into a Collaboration and License Agreement with Novo Nordisk A/S. The agreement became effective in July 2025 following antitrust clearance. Septerna received a $195.0 million upfront payment in July 2025. The company is eligible for up to $498.0 million in milestone payments per R&D program and tiered royalties.
• Vertex Milestone: In July 2025, a milestone event under the Vertex Asset Purchase Agreement was achieved, resulting in a $12.5 million payment received in August 2025.
• Liquidity Outlook: Management believes that existing cash, cash equivalents, and marketable securities ($379.2 million as of June 30, 2025), combined with the Novo upfront payment and Vertex milestone, will be sufficient to fund operations and capital expenditures at least into 2029.
• Tax Legislation: The "One Big Beautiful Bill Act" (H.R.1) was signed into law on July 4, 2025, introducing changes to the U.S. federal income tax code, including modifications to R&D expense capitalization. The company is evaluating the impact on its financial statements.
• Risk Factors: Risks include potential disruptions at the FDA due to staffing reductions, geopolitical instability, trade tariffs, and the inherent uncertainties of drug development and clinical trials.

Investor Verification Checklist

• Verify the accounting treatment and revenue recognition timeline for the $195.0 million Novo Nordisk upfront payment received in July 2025.
• Confirm the status and future funding requirements for the SEP-631 (MRGPRX2) and PTH1R programs following the discontinuation of SEP-786.
• Assess the impact of the new H.R.1 tax legislation on future deferred tax assets and R&D expense deductibility.
• Monitor the company's cash burn rate relative to the projected runway into 2029, considering the timing of future milestone payments.
• Review the details of the Novo Nordisk collaboration regarding the specific targets (GLP-1, GIP, glucagon receptors) and the division of development responsibilities.